Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
NoteHC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Gubra

437

 

DKK

 

-8.58 %

Less than 1K followers

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
-8.58%
-32.77%
-29.97%
-28.83%
-12.6%
+55.52%
-
-
+297.27%

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Read more
Market cap
7.14B DKK
Turnover
25.04M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 17.03.2025

Financial calendar
3.4.
2025

General meeting '25

21.8.
2025

Interim report Q2'25

27.2.
2026

Annual report '25

All
Research
Webcasts
Press releases
ShowingAll content types
Gubra: Understanding valuation (PoS) post Abbvie deal
Video8 hours ago by
Philip Coombes, Claus Thestrup

Gubra: Understanding valuation (PoS) post Abbvie deal

The company combines the best of both worlds – a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential. With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in – and what could unlock further development? 

Gubra
Gubra (One-pager): From Biotech to Techbio
Research3/17/2025, 7:07 AM by
Philip Coombes, Claus Thestrup

Gubra (One-pager): From Biotech to Techbio

Gubra (One-pager): From Biotech to Techbio

Gubra
Gubra – Peer News from Zealand Pharma
Analyst Comment3/13/2025, 5:36 AM by
Claus Thestrup

Gubra – Peer News from Zealand Pharma

Gubra – Peer News from Zealand Pharma

Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release3/10/2025, 11:57 AM

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025

Gubra
Regulatory press release3/3/2025, 6:08 AM

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

Gubra
Regulatory press release2/28/2025, 6:30 AM

Annual Report 2024: Excellent performance across Gubra

Gubra
Press release1/15/2025, 6:30 AM

Gubra appoints new Chief Operating Officer

Gubra
Press release12/30/2024, 12:30 PM

Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist

Gubra
Regulatory press release11/13/2024, 5:36 PM

Gubra announces positive GUBamy Phase 1 SAD data (correction)

Gubra
Regulatory press release11/13/2024, 4:41 PM

Gubra announces positive GUBamy Phase 1 SAD data

Gubra
Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos
Analyst Comment11/8/2024, 9:46 AM by
Claus Thestrup

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Gubra
Gubra – Presentation of Q3 2024
Webcast11/7/2024, 11:00 AM by
Claus Thestrup

Gubra – Presentation of Q3 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 AM when they present the Q3 report 2024. Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Gubra
Gubra: Another strong quarter in CRO and pipeline update
Analyst Comment11/7/2024, 8:04 AM by
Claus Thestrup

Gubra: Another strong quarter in CRO and pipeline update

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here.

Gubra
Regulatory press release11/7/2024, 6:30 AM

Trading statement Q3-2024: Another strong quarter

Gubra
Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation
Analyst Comment10/31/2024, 1:04 PM by
Claus Thestrup

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation

Boehringer Ingelheim, Gubra's partner in multiple obesity projects, has decided to discontinue the clinical obesity project NYP2.

Gubra
Regulatory press release10/31/2024, 10:07 AM

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra
Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates
Research9/9/2024, 2:02 PM by
Philip Coombes, Claus Thestrup

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

We have revised our DCF-model, guided by the company, to reflect new estimates for the total obesity market in 2030. With the current share price in line with our latest one-pager from June 2024, the model indicates a lower probability og success (PoS) in the base case.

Gubra
Regulatory press release9/6/2024, 7:42 PM

Major shareholder announcement

Gubra
Gubra - Presentation of Q2 report 2024
Webcast8/23/2024, 11:00 AM by
Claus Thestrup

Gubra - Presentation of Q2 report 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 23 August at 13.00 when they present the Q2 report 2024.

Gubra
Regulatory press release8/22/2024, 5:30 AM

Interim report H1 2024: Strong performance across Gubra

Gubra
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.